Bausch & Lomb forks over $500M for ISTA; Blood protein eyed as drug delivery vehicle;

> Bausch & Lomb ($BOL) is paying $500 million for ISTA Pharmaceuticals ($ISTA), giving it access to various eye drop and other ophthalmic treatments for sale or under development. Story

> Novozymes Biopharma, in conjunction with researchers in Norway, the U.K. and in New Zealand, is exploring how the blood protein serum albumin might be harnessed to deliver or transport medications around the body. Release

> Axxia Pharmaceuticals is developing a button-sized device, implanted under the skin, designed to deliver extended pain relief medication for up to three months. Story

> Drug delivery company Impax Laboratories ($IPXL) will work with TOLMAR to develop, supply and distribute "alternative dosage form products." Release

> Ikaria gained 510(k) clearance to use its two drug delivery systems with three more respiratory care devices. The company's Inomax DS and DSIR products deliver Inomax (nitric oxide) for inhalation to treat infants with hypoxic respiratory failure. Release

> India's Ideal Cures has obtained a U.S. patent for an aqueous film coating meant to enable effective release of a treatment from various pharmaceuticals and nutraceuticals. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.